Thyroglobulin Value Predict Iodine-123 Imaging Result in Differentiated Thyroid Cancer Patients.
Alfredo CampenníRosaria Maddalena RuggeriMassimiliano SiracusaDavide RomanoGiulia GiacoppoLudovica CrocèHelena RosarnoSimona RussoDavide CardileFrancesca CapoccettiAngela AlibrandiSergio BaldariLuca M GiovanellaPublished in: Cancers (2023)
Background: In differentiated thyroid cancer (DTC) patients, the response to initial treatments is evaluated 6-12 months after radioiodine therapy (RIT) according to the 2015 American Thyroid Association (2015 ATA) criteria. In selected patients, diagnostic 131-radioiodine whole-body scintigraphy (Dx-WBS) is recommended. We evaluated the diagnostic performance of 123 I-Dx-WBS-SPECT/CT imaging in detecting incomplete structural responses in the early follow-up of DTC patients and, additionally, derived optimized basal-Tg value as a yardstick for scintigraphic imaging. Methods: We reviewed the records of 124 low or intermediate-risk DTC patients with negative anti-thyroglobulin antibody. All patients had undergone (near)-total-thyroidectomy followed by RIT. The response to initial treatments was evaluated 6-12 months after RIT. Results: According to the 2015 ATA criteria, 87, 19 and 18 DTC patients were classified to have excellent response (ER), indeterminate/incomplete biochemical response (BIndR/BIR) or structural incomplete response (SIR), respectively. Among patients with less than ER, 18 had a positive 123 I-Dx-WBS-SPECT/CT. Metastatic disease at 123 I-Dx-WBS-SPECT/CT mainly involved lymph nodes within the central compartment, and corresponding neck ultrasound examinations were negative. The ROC curve analysis was performed to define the best basal-Tg cut-off (i.e., 0.39 ng/mL; AUC = 0.852) able to discriminate patients with and without positive 123 I-Dx-WBS-SPECT/CT, respectively. The overall sensitivity, specificity, accuracy, PPV and NPV were 77.8%, 89.6%, 87.9%, 56.0% and 95.9%, respectively. Basal-Tg cut-off was an independent risk factor for having a positive 123 I-Dx-WBS-SPECT/CT. Conclusion: 123 I-Dx-WBS-SPECT/CT identified lymph node metastases in 14/37 patients with less than ER and a negative neck ultrasound, thus modifying the management of such patients. The diagnostic performance of 123 I-Dx-WBS-SPECT/CT significantly increased in patients with basal-Tg values ≥ 0.39 ng/mL.
Keyphrases
- end stage renal disease
- lymph node
- newly diagnosed
- ejection fraction
- computed tomography
- chronic kidney disease
- prognostic factors
- early stage
- pet ct
- image quality
- squamous cell carcinoma
- dual energy
- magnetic resonance
- magnetic resonance imaging
- patient reported outcomes
- rectal cancer
- high resolution
- patient reported
- mesenchymal stem cells
- photodynamic therapy